EP4069244A4 - Use of reboxetine to treat nervous system disorders - Google Patents
Use of reboxetine to treat nervous system disorders Download PDFInfo
- Publication number
- EP4069244A4 EP4069244A4 EP20895126.9A EP20895126A EP4069244A4 EP 4069244 A4 EP4069244 A4 EP 4069244A4 EP 20895126 A EP20895126 A EP 20895126A EP 4069244 A4 EP4069244 A4 EP 4069244A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title 1
- 229960003770 reboxetine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943077P | 2019-12-03 | 2019-12-03 | |
US201962946295P | 2019-12-10 | 2019-12-10 | |
US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4069244A1 EP4069244A1 (en) | 2022-10-12 |
EP4069244A4 true EP4069244A4 (en) | 2023-12-20 |
Family
ID=81851750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20895126.9A Pending EP4069244A4 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4069244A4 (en) |
JP (1) | JP2023504685A (en) |
KR (1) | KR20220108122A (en) |
CN (1) | CN114746097A (en) |
AU (1) | AU2020395082A1 (en) |
BR (1) | BR112022010677A2 (en) |
CA (1) | CA3163505A1 (en) |
CO (1) | CO2022007507A2 (en) |
CR (1) | CR20220247A (en) |
IL (1) | IL293536A (en) |
MX (1) | MX2022006630A (en) |
PE (1) | PE20230181A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60035232T2 (en) * | 1999-07-01 | 2008-02-14 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S, S) reboxetine for the treatment of chronic fatigue syndrome |
PL197981B1 (en) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Application of optically pure (S,S)-reboxetine and the pharmaceutically acceptable salts thereof for drug preparation |
NZ581707A (en) * | 2007-05-07 | 2011-05-27 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
DK2968208T3 (en) * | 2013-03-13 | 2022-08-22 | Jazz Pharmaceuticals Ireland Ltd | TREATMENT OF CATAPLEXIA |
-
2020
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/en unknown
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/en unknown
- 2020-11-30 CR CR20220247A patent/CR20220247A/en unknown
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/en unknown
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/en active Pending
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/en unknown
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/en active Pending
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en active Pending
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/en unknown
Non-Patent Citations (4)
Title |
---|
GARCIA-BORREGUERO D ET AL: "567.K Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP; 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, ALLEN PRESS, LAWRENCE, KS, US, vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), pages A323 - A324, XP009531711, ISSN: 0161-8105 * |
O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 * |
SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 * |
See also references of WO2021113163A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN114746097A (en) | 2022-07-12 |
IL293536A (en) | 2022-08-01 |
CA3163505A1 (en) | 2021-06-10 |
JP2023504685A (en) | 2023-02-06 |
PE20230181A1 (en) | 2023-02-01 |
AU2020395082A1 (en) | 2022-06-09 |
KR20220108122A (en) | 2022-08-02 |
EP4069244A1 (en) | 2022-10-12 |
BR112022010677A2 (en) | 2022-08-16 |
CO2022007507A2 (en) | 2022-06-21 |
MX2022006630A (en) | 2022-06-24 |
CR20220247A (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4010072A4 (en) | Treatment of central nervous system disorders | |
EP3526319A4 (en) | Compositions and methods for treating diseases and disorders of the central nervous system | |
EP3259017A4 (en) | Nerve stimulation for treatment of diseases and disorders | |
EP3389725A4 (en) | Compositions and methods for treatment of central nervous system diseases | |
EP3618824A4 (en) | Use of n-acetylcysteine to treat central nervous system disorders | |
EP3429605A4 (en) | Therapeutic for treatment of diseases including the central nervous system | |
EP3596063A4 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
EP3579830A4 (en) | Cannabinoid-containing fatty acid formulations for treating disorders of the nervous system | |
EP3507371A4 (en) | Methods and compositions for treating diseases and disorders of the nervous system | |
EP3700525A4 (en) | Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress | |
EP3270914A4 (en) | Compounds and forms of treatment for female sexual disorders | |
EP3826650A4 (en) | Methods of treating neurological disorders | |
EP3914231A4 (en) | Treatment of skin disorders with topical tapinarof combination compositions | |
CA3082254A1 (en) | Heterocyclic compounds as kinase inhibitors | |
EP3856169A4 (en) | Methods of treating myeloproliferative disorders | |
EP3826649A4 (en) | Methods of treating neurological disorders | |
EP4069847A4 (en) | Treatment of lower airways disorders | |
IL283503A (en) | Combined treatment of primary central nervous system lymphoma | |
EP3634370A4 (en) | Treatment of cutaneous disorders | |
EP3927428A4 (en) | Methods of treatment of respiratory disorders | |
EP3911313A4 (en) | Thienyl-aniline compounds for treatment of dermal disorders | |
GB201914034D0 (en) | Treatment of neurological disorders | |
EP3856198A4 (en) | Low-intensity treatment of hematological disorders | |
EP3866768A4 (en) | Use of reboxetine to treat narcolepsy | |
EP3709982A4 (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220628 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40080135 Country of ref document: HK |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231122 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 43/00 20060101ALI20231116BHEP Ipc: A61P 25/00 20060101ALI20231116BHEP Ipc: A61P 25/24 20060101ALI20231116BHEP Ipc: A61K 31/5375 20060101AFI20231116BHEP |